Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received clearance...
Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National...
Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval...
Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing...
Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in...
Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease
Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for...
Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition
Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to...
Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform
Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech...
Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy
Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved...
AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations
AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase...
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline
Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc....
Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability
Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers...
Gan & Lee Pharmaceuticals’ Once-Weekly Insulin GZR4 Demonstrates Superior HbA1c Reduction in Phase III Trials
Gan & Lee Pharmaceuticals (SHA: 603087) announced that two pivotal Phase III clinical studies, SUPER-1...
Abbisko Therapeutics Secures EMA Orphan Drug Designation for Irpagratinib in Hepatocellular Carcinoma
Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the European Medicines Agency (EMA) has granted...
MicroPort Scientific Returns to Profitability as Global Access Platform Drives 78.8% Revenue Surge
MicroPort Scientific Corp. (HKG: 0853) announced its 2025 full-year financial results, reporting a return to...
Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic
Amoy Diagnostics Co., Ltd. (SHE: 300685) and HutchMed (China) Ltd. (NASDAQ: HCM, HKG: 0013) have...
Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care
Abbott (NYSE: ABT) has announced a strategic collaboration with Flatiron Health, a leading oncology health...
Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors
Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I...
Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures
Boston Scientific (NYSE: BSX) has announced FDA 510(k) clearance for its Asurys Fluid Management System,...
Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs
Kailera Therapeutics has announced plans for an initial public offering (IPO) to secure additional funding...